民间投资结构持续优化 呈现向实向新趋势 基础设施民间投资稳步增加 2025年1-11月 基础设施民间投资同比增长3.5% 其中 增长 水利管理业民间投资 34.2% 增长 航空运输业民间投资 25.1% 2025年,超长期特别国债规模达到 1.3万亿元 相比2024年 7 万亿元大幅增长 8000 亿元 其中 用于更大力度支持"两重"项目 5000 亿元 用于加力扩围实施"两新"政策 2026年,继续实施更加积极的财政政策 将优化政府投资方向,围绕打基础、利长远、补短板、 调结构加大力度,鼓励吸引民间资本参与重大项目建设, 推动扩大有效投资。增强政府性融资担保能力,加大对 民间投资支持力度。 2025年11月末社会融资规模存量为 440.07 万亿元 对实体经济发放的 同比增长 人民币贷款 6.3% 三李度末 银行业金融机构 同比增长 普惠型小微企业贷款 2.1% 2026年,继续实施适度宽松的货币政策 加快推进金融供给侧结构性改革。灵活高效运用 民间投资是稳增长、调结构、促就业的重要支撑力量。2025年，各地区各部门落实更加积极有为的宏观 政策，把政策红利实实在在送到经营主体手中，持续激发民间投资活力，促进 ...

中新网新疆新闻12月29日电（姚明）2025年，紧扣地委对乌苏"工业强市走在前"的战略定位，乌苏市立 足丝绸之路经济带核心区重要节点优势，以中新（重庆）互联互通多式联运示范项目中亚专线乌苏中转 基地正式投用契机，紧抓新疆塔城重点开发开放试验区等战略机遇，构建起合成生物制造、智能装备制 造、棉花纺织服装等产业集群协同发展的现代产业体系，勾勒出"工业强市"的壮阔图景：4月，新疆首 个合成生物制造产业集聚区在乌苏挂牌，成为全国第四个合成生物产业集聚区；7月，新疆钵施然智能 农机的一批国产采棉机出口乌兹别克斯坦，彰显中国农机制造实力；2025年乌苏啤酒市场综合占有率在 新疆区域内达到90%以上，番茄制品畅销国内外……一组组亮眼成绩的背后，是乌苏市工业经济高质量 发展的强劲脉动。 合成生物：打造西部"生物制造"新高地 当传统的农业资源与现代生物科技相遇，会碰撞出怎样的产业火花？乌苏以"合成生物制造"这一战略性 新兴产业，给出了响亮的答案。2025年4月26日，新疆合成生物制造产业集聚区发布会在乌苏召开，科 学规划"一核三区"空间布局，乌苏工业园区作为"一核"，成为产业发展的核心承载地。 龙头企业引领产业链延伸。新疆合成 ...

Core Insights - The concept of "new quality productivity" is deeply embedded in the economic structure, driving industrial transformation and innovation in listed companies [2][9] - Over 2,200 A-share companies have included "new quality productivity" in their 2024 annual reports, indicating a widespread commitment to optimizing traditional industries and fostering emerging sectors [2][9] Traditional Industry Transformation - Companies are not starting from scratch but are innovating existing industries through new technologies and paradigms, addressing challenges like capacity overflow and homogenized competition [2][4] - Examples include Jack Technology's shift towards AI sewing machines and humanoid robots, and Hengsheng Energy's entry into the diamond production sector through its subsidiary [3][4] Emerging Industry Ecosystem - Under the dual drive of policy and market forces, listed companies in strategic emerging industries like new energy and materials are moving from single-point innovations to systemic capabilities [5] - Sunshine Power's 7.8GWh project in Saudi Arabia set an industry record by completing production and delivery in just 58 days, showcasing the rapid advancement in the energy sector [5] Future Industry Strategic Positioning - Companies are investing in advanced fields such as quantum technology, biomanufacturing, and 6G to secure technological leadership [7][9] - For instance, Chuangyuan Xinke is actively involved in 6G core technology development, while Kexai Biotech is focusing on bio-based materials to replace traditional fossil-based products [7][8] Overall Industry Trends - The transformation narrative of listed companies is characterized by three clear paths: traditional industries innovating through engineering advantages, emerging industries building cluster ecosystems, and future industries positioning themselves through advanced R&D [9][10] - The valuation paradigm in capital markets is shifting, with company value increasingly defined by technological barriers, industry ecosystem positioning, and future potential rather than just current profits [9][10]

来源：钛媒体 图 片由AI生成 2025年的合成生物产业，在喧嚣中沉淀，在挑战中前行。 市场规模的持续扩容，印证着这一赛道的巨大产业价值——全球合成生物学市场规模预计在今年达到245.8亿美元，2027年将增至387亿美元，2032年有望冲 破千亿美元大关；中国市场的增长曲线更显陡峭，从2016年的9亿美元跃升至2021年的64亿美元，今年预计突破70亿美元，未来仍将保持高速增长态势。 与传统吃药、打针的治疗逻辑不同，CAR-T堪称"细胞级精准武器"的医疗革命，通过提取患者自身免疫细胞，在实验室中改造训练后再回输体内作战，正是 合成生物学的崛起及其工程化思维和可控基因线路的引入，才为CAR-T疗法带来了创新的改造方向。若把CAR-T比作抗癌士兵，合成生物学就是给士兵升级 装备和战术，让它们能精准感知、应对肿瘤微环境的挑战。世界经济论坛《2025年十大新兴技术》报告将"工程化活体疗法"纳入新一代健康生物技术领域， 这项技术通过合成生物学与精准医疗的深度融合，利用人工设计的有益细菌在人体内执行治疗功能，既能降低长期医疗成本，又能显著改善疗效。 镜头拉远，作为一门多学科交叉的底层技术，合成生物学打破传统学科界限，融 ...

浦江蜿蜒，润泽上海多个产业园区；浪涛汹涌，击打出创新的节拍；货轮远航，驶向广阔的国际市 场……"十五五"规划建议擘画出未来五年的战略蓝图，一批上海科创公司为国担当、勇为尖兵，瞄准创 新与国际化"双线突围"，谋篇布局高质量发展。 硬核创新是扎根本土的底气。上海完善的科创生态，为企业攻坚"卡脖子"技术提供了肥沃土壤。乘着上 海支持创新创业的东风，80后的大学生创业者谢应波带领泰坦科技，在科学服务行业闯出一条国产化之 路；从生物材料到生物制造，凯赛生物手握颠覆性创新技术，大胆挺进合成生物产业蓝海；面对"数据 危机"带来的挑战，英方软件接连翻越研发、市场与信任"三座山"，以硬实力打造数据"保险栓"；20年 精耕细作，从3G到6G，创远信科不断夯实通信测试技术底座，用"工业之尺"刻画着产业新高度。 开放布局是链接全球的桥梁。依托上海国际科创中心的优势，科创企业家不约而同将未来五年的发展目 光投向国际市场。凯赛生物董事长刘修才说，公司要成为世界生物制造产业的开拓者，并培养中国生物 制造的同路人。在泰坦科技的"征途墙"上，董事长谢应波为"十五五"之路贴上了一个新的关键词 ——"出海"。面对海外客户对中国基础软件的偏见，英方 ...

（原标题：粤科金融集团推动"补改投"首批意向项目签约） 南方财经记者庞成 见习记者王达毓 广州报道 12月7日下午，2025大湾区科学论坛科技金融分论坛在广州南沙成功举办。在以"新质湾区 金融聚力"为主题的论坛现场，广东省粤科金融集团有 限公司旗下粤科创新创业投资管理有限公司与七家科技企业隆重签署"补改投"项目投资意向协议，标志着广东省重点领域研发计划资金"补改 投"专项迈出关键一步。据了解，广东省科技厅牵头设立重点领域研发计划资金"补改投"专项，并由省财政厅负责预算编制与绩效审核，粤科金融 集团协助项目库建设与考评监督。 本次签约围绕人工智能、智能机器人、生物医药等前沿方向，甄选出一批具备突破性技术和产业引领潜力的创新企业，以股权投资的创新模式， 精准赋能技术攻关与成果转化。 在人工智能领域，签约项目聚焦于脑机接口、高端检测设备与安全芯片三个关键环节。 华南脑控（广东）智能科技有限公司致力于攻克非侵入式脑机接口技术难题，旨在研发低功耗、高精度的可穿戴脑电采集与解码系统，突破国外 在高端脑电设备上的垄断。其技术未来可应用于意识障碍患者交流、抑郁症筛查、中风康复等多个临床场景，市场前景广阔，已在多家重点医院 开 ...

（原标题：国投、招商局参与 生物制造领域唯一国家级产业创新中心试运行） 21世纪经济报道记者 陈思琦 深圳报道 深圳迎又一国家级平台落地。 12月4日，在由深圳市政府主办的"光明科学城论坛·2025"开幕式上，国家生物制造产业创新中心启动试 运行。据悉，该中心由中国科学院深圳先进技术研究院牵头组建，是我国生物制造领域唯一的国家级产 业创新平台。 会上介绍，中心将围绕绿色低碳、生物农业、医疗健康三大领域，建设自动化生物制造平台、跨尺度生 物多模态验证平台、生产工艺高通量开发平台、中试放大及GMP平台、大规模载体制备与质控平台、 生物信息计算支撑平台等六大技术平台，助力实验室创意进入新产品创制的"0—1—10"进程。 当前，深圳已集聚合成生物研究重大科技基础设施、深圳市工程生物产业创新中心、深圳理工大学合成 生物学院等各类产学研平台。《深圳市生物制造发展白皮书（2025）》显示，近三年，中国每新成立 100家生物制造企业，就有40家在深圳，其中30家在光明区。 事实上，参与共建的两大央企，对生物制造领域的关注和布局由来已久。 招商局集团官网显示，集团牵头承担国务院国资委焕新行动生物制造专项，"系列生物基聚酰胺开发 ...

Group 1: Market Overview - Recent adjustments in technology stocks have led to a relatively volatile market, with trading activity cooling down and retail investors showing net outflows [2][4] - Private equity funds have shown a strong willingness to allocate capital, with the number of registered funds increasing to 286 last week, marking a rebound [2] - Public funds have also shown signs of a trend reversal in their positions since mid-October [2] Group 2: Fixed Income Insights - In the first week of November, both new and second-hand housing transactions have declined, with new home sales at seasonal lows, indicating a need for price improvement [4][5] - Industrial freight volumes have slightly decreased, but production rates remain strong, with most sectors showing year-on-year increases [4] - The real estate sector is advised to focus on high-grade state-owned enterprise bonds for investment, given the current market conditions [5] Group 3: Technology and AI Developments - The 2026 Investment Summit highlighted a new acceleration in global computing power construction, driven by expanding inference demand and innovative financing models [6][7] - The AI industry is entering a new paradigm, with synthetic data breaking training data ceilings and commercial applications scaling up [7] Group 4: Machinery and Equipment - In October 2025, excavator sales reached 18,100 units, a year-on-year increase of 7.8%, but growth has slowed compared to September [8] - Domestic demand is expected to recover, supported by rapid growth in second-hand excavator exports [8] Group 5: Renewable Energy and Storage - The State Council's white paper emphasizes the importance of new energy storage in achieving carbon neutrality goals, highlighting three key areas for investment: new energy + storage, grid upgrades, and traditional power sources [11] Group 6: Communication Sector - The communication sector showed steady growth in Q3 2025, with revenue and net profit increasing by 5.2% and 12.3% year-on-year, respectively [14] - Future growth is expected to be driven by increased investment in AI computing power and the expansion of telecommunications operators [14] Group 7: Environmental Testing Industry - The third-party testing and inspection industry is anticipated to see a performance growth inflection point in Q4 2025, driven by policy support and emerging demand [16] - Key companies to focus on include Su Shi Testing and Huace Testing, which are expected to show clear performance rebounds [16] Group 8: Company-Specific Insights - Kaisa Biotech has been initiated with a "Buy" rating, targeting a price of 64.90 yuan, benefiting from its leading position in the biomanufacturing sector [19][16] - Hualu Hengsheng is expected to see improved market conditions for oxalic acid and caprolactam, maintaining a "Buy" rating [18]

Core Viewpoint - 凯赛生物's Q3 2025 report shows overall growth in revenue and profit, driven by the increasing sales of long-chain dicarboxylic acid products [2][4]. Financial Performance - For the first three quarters, the company achieved total revenue of 2.545 billion yuan, a year-on-year increase of 14.90% [2][3]. - The net profit attributable to shareholders reached 451 million yuan, up 30.56% year-on-year [2][3]. - The net profit excluding non-recurring gains and losses was 429 million yuan, reflecting a 27.83% increase [2][3]. - The total profit for the period was 161 million yuan, showing a significant increase of 51.46% [3]. - Basic and diluted earnings per share were both 0.20 yuan, a rise of 17.65% [3]. Product and Market Development - 凯赛生物 is a leading company in long-chain dicarboxylic acids, with its DC11-DC18 products dominating the global market [4]. - The company utilizes biomanufacturing methods to produce various products, which have gained customer acceptance due to superior quality, pricing, and carbon reduction effects [4]. - The introduction of innovative compounds like pentamethylenediamine and the development of bio-based polyamides and composites are expected to create a second growth curve for the company [4]. Green Composite Materials - 凯赛生物 has launched the world's first bio-based composite cold storage container, marking a significant step in its green composite materials strategy [4]. - The company’s bio-based composite materials have penetrated six major sectors, including new energy vehicles, clean energy, rail transportation, construction, electronics, and consumer goods [4]. - The shift towards green composite materials is driven by high carbon emissions from traditional petroleum-based composites, aligning with dual carbon policies [5]. Industry Trends - The green composite materials market is poised for growth as companies like 凯赛生物 innovate to meet sustainability goals while maintaining product performance [5]. - The upcoming "2025 (Fourth) Green Composite Materials Forum" will focus on technological breakthroughs and industry integration in the green composite sector [6].

Core Insights - Material innovation is a key driver of modern technological development, with China's new materials industry showing diverse and specialized growth under policy guidance and support [1][2] - The industry is experiencing intensified competition, with companies focusing on differentiated strategies to break through the "involution" phenomenon, emphasizing R&D and high-end breakthroughs as critical approaches [11][12] Industry Development - The new materials sector is characterized by interdisciplinary collaboration, involving materials science, physics, chemistry, and biology, with companies like Nanya New Materials, Huaqin Technology, Lianrui New Materials, and Kaisa Bio focusing on national strategic needs and core technology breakthroughs [2][3] - Nanya New Materials has been a key player in the copper-clad laminate market for 25 years, with products essential for electronic manufacturing, particularly in communications, AI, and automotive sectors [2][3] - Huaqin Technology specializes in aerospace materials and has expanded its offerings to include high-performance composite materials and advanced ceramics, with over 90% of its revenue derived from materials [2][3] Company Strategies - Huaqin Technology has established partnerships with various research institutions to enhance its R&D capabilities and fill domestic technology gaps, achieving significant progress in self-sufficiency [3][6] - Lianrui New Materials focuses on silicon and aluminum-based materials, optimizing product performance through intelligent transformation and entering international supply chains [3][12] - Kaisa Bio has developed bio-based materials, including bio-based nylon, and aims to replace traditional materials in various industries, highlighting its long-standing expertise in the field [4][5] Policy Support - The past five years have seen significant policy support for the copper-clad laminate industry, leading to a reduction in reliance on overseas supply chains and advancements in domestic production capabilities [5][6] - Policies promoting innovation and technology transfer have facilitated the growth of companies like Huaqin Technology, enabling them to expand their product offerings and market reach [6][7] Market Trends - The rise of AI and advancements in bio-manufacturing are accelerating the domestic production of electronic materials and bio-based products, with expectations for the domestic electronic materials market to surpass North America and Europe [8][9] - By 2025, Nanya New Materials anticipates significant growth in output and revenue driven by domestic demand for AI computing power [9][10] - Kaisa Bio is positioned as a global leader in bio-manufacturing, with plans to increase production capacity for long-chain dicarboxylic acids significantly by 2025 [10][11] Competitive Landscape - The new materials industry is witnessing heightened competition, with companies adopting differentiated strategies focused on R&D and high-end product development to maintain market positions [11][12] - Huaqin Technology and Lianrui New Materials are both investing heavily in R&D to secure technological advantages and expand into high-end markets [11][12] - Kaisa Bio emphasizes the importance of balancing technological uniqueness with market demand to achieve stable profitability in the competitive landscape of synthetic biology [13]